Narendra Bagri | Clinical Trials | Best Researcher Award

Published on by Top Pharmaceutical

Assoc. Prof. Dr. Narendra Bagri | Clinical Trials | Best Researcher Award

All India Institute of Medical Sciences | India

Assoc. Prof. Dr. Narendra Bagri is a distinguished clinician and academician in the field of pediatric rheumatology, presently serving as Additional Professor in the Department of Pediatrics, Division of Pediatric Rheumatology at the All India Institute of Medical Sciences (AIIMS), New Delhi, India. A graduate and postgraduate of the Institute of Medical Sciences, Banaras Hindu University, he has built a remarkable career through a blend of clinical excellence, teaching, and groundbreaking research in pediatric autoimmune and inflammatory disorders. He completed the prestigious PRES EMERGE Fellowship in Pediatric Rheumatology at the Bristol Royal Hospital for Children, UK, under the mentorship of Prof. A.V. Ramanan, enhancing his expertise in advanced pediatric rheumatologic care and translational research.Dr. Bagri’s scientific contributions encompass numerous impactful publications addressing critical aspects of pediatric inflammatory diseases, musculoskeletal imaging, and immunological mechanisms underlying juvenile idiopathic arthritis. His research includes the longitudinal analysis of multisystem inflammatory syndrome in children temporally related to COVID-19, the evaluation of pulse dexamethasone therapy in non-systemic juvenile idiopathic arthritis, and the technical and interpretive insights into pediatric musculoskeletal ultrasound. He has also authored work on the utility of musculoskeletal ultrasound in juvenile idiopathic arthritis, the forgotten figure in the history of methotrexate, sympathetic blocks for Raynaud’s phenomena in pediatric rheumatological disorders, and the conception of a national biologics registry for pediatric rheumatology.As a principal investigator and collaborator in multiple funded research projects by the Indian Council of Medical Research (ICMR) and the Science and Engineering Research Board (SERB), Dr. Bagri has contributed extensively to the understanding of synovial fluid proteomics, biomarker discovery, and immune-pathogenic mechanisms in childhood arthritis. His pioneering efforts include the development of transitional care services, collaborative rheumatology clinics, and the initiation of diagnostic and therapeutic procedures such as ultrasound-guided intra-articular injections and synovial biopsies.Dr. Bagri is a life member of several professional bodies, including the Indian Rheumatology Association, the Pediatric Rheumatology European Society, and the Indian Academy of Pediatrics. Recognized for his outstanding contributions, he has received multiple academic honors, travel grants, and leadership roles in national guideline formulation, including contributions to WHO and IAP documents on pediatric inflammatory syndromes. His dedication to research, patient care, and education continues to shape the evolution of pediatric rheumatology in India and beyond.

Profile: Google Scholar

Featured Publications

Bagri, N. K., Jose, B., Shah, S. K., Bhutia, T. D., Kabra, S. K., & Lodha, R. (n.d.). Impact of malnutrition on the outcome of critically ill children. The Indian Journal of Pediatrics, 82(7), 601–605.

Sivasubbu, S., & Scaria, V. (n.d.). Genomics of rare genetic diseases—experiences from India. Human Genomics.

Basu, S., Kumar, A., Kapoor, K., Bagri, N. K., & Chandra, A. (n.d.). Neonatal endogenous endophthalmitis: A report of six cases. Pediatrics.

Bagri, N., Saha, A., Chandelia, S., Dubey, N. K., Bhatt, A., Rai, A., & Bhattacharya, S. (n.d.). Fireworks injuries in children: A prospective study during the festival of lights. Emergency Medicine Australasia.

Bagri, N. K., Yadav, D. K., Agarwal, S., Aier, T., & Gupta, V. (n.d.). Pericardial effusion in children: Experience from tertiary care center in northern India. Indian Pediatrics.

Kumar, A., Bagri, N. K., Basu, S., & Asthana, R. K. (n.d.). Zinc supplementation for neonatal hyperbilirubinemia: A randomized controlled trial. Indian Pediatrics.

Bagri, N. K., Deepak, R. K., Meena, S., Gupta, S. K., Prakash, S., Setlur, K., Satapathy, J., Chopra, K., Upadhyay, A. D., Ramakrishnan, S., Lodha, R., Dar, L., Trikha, A., & Kabra, S. K. (n.d.). Outcomes of multisystem inflammatory syndrome in children temporally related to COVID-19: A longitudinal study. Rheumatology International.

Gupta, D., Thakral, D., Kumar, P., Kabra, S. K., Lodha, R., Kumari, R., Mohanty, S. K., … & Bagri, N. K. (n.d.). Primary immunodeficiency disorders among north Indian children. The Indian Journal of Pediatrics.

Shadi Hamoud | Clinical Trials | Excellence in Research Award

Published on by Top Pharmaceutical

Dr. Shadi Hamoud | Clinical Trials | Excellence in Research Award

Rambam health care campus | Israel

Dr. Shadi Hamoud is a distinguished physician, clinical researcher, and academic leader whose career spans internal medicine, cardiovascular research, and translational medicine. Earning his medical degree with honors from the Faculty of Medicine at the Hebrew University in Jerusalem, Dr. Hamoud embarked on a professional journey characterized by clinical excellence, research innovation, and a deep commitment to medical education. Over the years, he has combined patient-centered care with groundbreaking research, focusing on lipoprotein oxidation, atherosclerosis, the role of the enzyme heparanase in kidney injury, fatty liver disease, and cardiovascular disorders, as well as pioneering clinical trials for novel oral anticoagulants, lipid-modifying agents, diabetes treatments, and therapies for emerging infectious diseases such as COVID-19.As Deputy Director of the Department of Internal Medicine E at Rambam Medical Center and Director of the Clinical Research Unit, Dr. Hamoud has overseen numerous national and international clinical studies, collaborating with leading pharmaceutical companies, including Bayer, Pfizer, Novartis, Sanofi, and AstraZeneca. His research portfolio reflects expertise in designing and conducting complex multicenter clinical trials addressing some of the most challenging issues in cardiovascular medicine and metabolic diseases. Additionally, his clinical consultancy roles across multiple departments at Rambam Health Care Campus highlight his interdisciplinary approach to medicine, ensuring that research findings translate effectively into improved patient outcomes.An accomplished educator, Dr. Hamoud has dedicated decades to training the next generation of physicians, serving as a clinical lecturer at the Technion-Israel Institute of Technology and mentoring medical students, interns, and graduate researchers. Under his supervision, numerous MD and basic science theses have been completed, exploring critical areas such as oxidative stress, endothelial dysfunction, liver steatosis, and the molecular pathways of atherosclerosis. His leadership as Program Director for the Internal Medicine Preparatory Course for National Licensing Examinations further reflects his commitment to academic excellence and medical training standards.

Profile: Orcid

Featured Publications

Hamoud, S., Hacker, I., Karram, T., Fokra, A., Kabala, A., & Abassi, Z. (2024). Gender-specific renoprotective pathways in αMUPA transgenic mice subjected to acute kidney injury. International Journal of Molecular Sciences.

Cohen-Segev, R., Nativ, O., Kinaneh, S., Aronson, D., Kabala, A., Hamoud, S., Karram, T., & Abassi, Z. (2023). Effects of angiotensin 1-7 and Mas receptor agonist on renal system in a rat model of heart failure. International Journal of Molecular Sciences.

Kinaneh, S., Hijaze, W., Mansour-Wattad, L., Hammoud, R., Zaidani, H., Kabala, A., & Hamoud, S. (2022). Heparanase inhibition prevents liver steatosis in E₀ mice. Journal of Clinical Medicine.

[Author names not fully provided]. (n.d.). Predictors of survival in subjects treated in the “shock room” of the emergency department in a tertiary medical center.